NTRANMSHealthcare·Diagnostics & Research#6 in industry

Natera, Inc.

Reports in 11d· 2026-05-07

-14.6% · 90d

$205.32

+1.57 (+0.77%)

News

(2)

April 2026

Apr 23, 20264 days agoARSHealthcare

Natera Reports Annual Results With Oncology Focus

NTRANatera, Inc.

# 🧾 What This Document Is You're looking at Natera's **Annual Report to Shareholders (ARS)**. Think of this as the company's official yearly "report card" that gets sent directly to its owners (the shareholders). This document is required by the SEC and is a comprehensive summary of the company's f

Read summaryView on SEC EDGAR

Apr 23, 20264 days agoDEF 14AHealthcare

NTRA Shareholders vote on directors and 3.2 million equity shares

NTRANatera, Inc.

# 🧾 What This Document Is This is Natera's **Definitive Proxy Statement (DEF 14A)** for its **2026 Annual Shareholder Meeting**. It outlines what shareholders will vote on, introduces board nominees, explains executive pay, and seeks approval for key company actions. Think of it as an **agenda an

Read summaryView on SEC EDGAR

Key Data

Market Cap$29.31B

Open$202.60

Prev Close$203.75

Day Range$201.94 – $207.79

52W Range$131.81 – $256.36

Volume584,202

P/E (TTM)—

EPS$-1.53

Dividend Yield—

Beta1.68

Profit Margin-9.03%

Revenue Growth39.80%

Price Target$258.00(+25.7%)

Next Earnings2026-05-07(11d)

Analyst Ratings

Strong Buy19 analysts

Buy 17Hold 2Sell 0

About

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Healthcare · Diagnostics & Research

6,135 employees

www.natera.com